Skip to main content

Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial.

Publication ,  Journal Article
Dawson, G; Sun, JM; Davlantis, KS; Murias, M; Franz, L; Troy, J; Simmons, R; Sabatos-DeVito, M; Durham, R; Kurtzberg, J
Published in: Stem Cells Transl Med
May 2017

Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (ASD) are needed. We hypothesized that umbilical cord blood-derived cell therapies may have potential in alleviating ASD symptoms by modulating inflammatory processes in the brain. Accordingly, we conducted a phase I, open-label trial to assess the safety and feasibility of a single intravenous infusion of autologous umbilical cord blood, as well as sensitivity to change in several ASD assessment tools, to determine suitable endpoints for future trials. Twenty-five children, median age 4.6 years (range 2.26-5.97), with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit, were enrolled. Children were evaluated with a battery of behavioral and functional tests immediately prior to cord blood infusion (baseline) and 6 and 12 months later. Assessment of adverse events across the 12-month period indicated that the treatment was safe and well tolerated. Significant improvements in children's behavior were observed on parent-report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye-tracking measures of children's attention to social stimuli, indicating that these measures may be useful endpoints in future studies. Behavioral improvements were observed during the first 6 months after infusion and were greater in children with higher baseline nonverbal intelligence quotients. These data will serve as the basis for future studies to determine the efficacy of umbilical cord blood infusions in children with ASD. Stem Cells Translational Medicine 2017;6:1332-1339.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Stem Cells Transl Med

DOI

ISSN

2157-6564

Publication Date

May 2017

Volume

6

Issue

5

Start / End Page

1332 / 1339

Location

England

Related Subject Headings

  • Male
  • Humans
  • Fetal Blood
  • Female
  • Child, Preschool
  • Cell- and Tissue-Based Therapy
  • Autism Spectrum Disorder
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dawson, G., Sun, J. M., Davlantis, K. S., Murias, M., Franz, L., Troy, J., … Kurtzberg, J. (2017). Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl Med, 6(5), 1332–1339. https://doi.org/10.1002/sctm.16-0474
Dawson, Geraldine, Jessica M. Sun, Katherine S. Davlantis, Michael Murias, Lauren Franz, Jesse Troy, Ryan Simmons, Maura Sabatos-DeVito, Rebecca Durham, and Joanne Kurtzberg. “Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial.Stem Cells Transl Med 6, no. 5 (May 2017): 1332–39. https://doi.org/10.1002/sctm.16-0474.
Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, et al. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl Med. 2017 May;6(5):1332–9.
Dawson, Geraldine, et al. “Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial.Stem Cells Transl Med, vol. 6, no. 5, May 2017, pp. 1332–39. Pubmed, doi:10.1002/sctm.16-0474.
Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, Simmons R, Sabatos-DeVito M, Durham R, Kurtzberg J. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Transl Med. 2017 May;6(5):1332–1339.

Published In

Stem Cells Transl Med

DOI

ISSN

2157-6564

Publication Date

May 2017

Volume

6

Issue

5

Start / End Page

1332 / 1339

Location

England

Related Subject Headings

  • Male
  • Humans
  • Fetal Blood
  • Female
  • Child, Preschool
  • Cell- and Tissue-Based Therapy
  • Autism Spectrum Disorder
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences